Navigating Third Rock's Maze

How genetic modifier play Maze plans to deploy $191M financing

After Third Rock Ventures incubated Maze Therapeutics for two years, the company debuted Thursday with $191 million and plans to generate data for its three genetic modifier programs in

Read the full 299 word article

User Sign In